# Medtronic and Tandem Diabetes Care enter patent cross-license agreement

Medtronic and Tandem Diabetes Care have entered into a non-exclusive patent cross-license agreement for diabetes technologies, covering existing and new products for at least five years, with no payments exchanged.

- Type: Partnership
- Announced: 2020-07-09
- Status: completed
- Products: insulin pumps, continuous glucose monitoring systems
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Medtronic plc](https://endata.com/companies/19071.md) (partner)
- [Tandem Diabetes Care](https://endata.com/companies/29150.md) (partner)

## Sources

- [news.medtronic.com](https://news.medtronic.com/2020-07-09-Medtronic-and-Tandem-Diabetes-Care-Enter-Into-Patent-Cross-License-Agreement), 2020-07-09: "Cross-licensing each other’s patent portfolios enables both companies to focus on helping people with diabetes through innovation of future products and services, while avoiding the distraction of potential legal disagreements."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.